IRF5 Monoclonal Antibody (ALYSCLN), eFluor™ 660, eBioscience™, Invitrogen™

Description

• Description: The ALYSCLN monoclonal antibody reacts with human IRF5, a 60-63 kDa member of the interferon regulatory factor family of transcription factors that have diverse roles in host defense against viruses
• IRF5 was originally identified as an important regulator of IFN alpha and IFN beta and more recently has been shown to be regulated by these interferons
• IRF5 is also involved in induction of pro-inflammatory cytokines including IL-6, IL-12 and TNF alpha in response to TLR signaling
• Specifically, it has been shown that MyD88 and TRAF6 interact directly with IRF5 in response to TLR activation and this interaction results in IRF5 nuclear translocation
• Additionally, IRF5 has been shown to have both p53-dependent and independent effects in regulation of cell cycle and apoptosis
• Genetic polymorphisms in the IRF5 locus have been implicated in many autoimmune diseases including Sjogren's syndrome, inflammatory bowel disease, multiple sclerosis and systemic lupus erythematosus
• Recently, a role for IRF5 in the polarization of classically activated (M1) macrophages has been identified
• In these macrophages, IRF5 directly upregulates expression of IL-12 and IL-23 and represses IL-10
• Moreover, exogenous expression of IRF5 in M2-polarized (alternatively activated) macrophages induces expression of M1-related cytokines and chemokines
• This gene encodes a member of the interferon regulatory factor (IRF) family, a group of transcription factors with diverse roles, including virus-mediated activation of interferon, and modulation of cell growth, differentiation, apoptosis, and immune system activity
• Members of the IRF family are characterized by a conserved N-terminal DNA-binding domain containing tryptophan (W) repeats
• Alternative splice variants encoding different isoforms exist.